A multicenter study confirms CD226gene association with systemic sclerosis-related pulmonary fibrosis by Bossini Castillo, Lara et al.
RESEARCH ARTICLE Open Access
A multicenter study confirms CD226 gene
association with systemic sclerosis-related
pulmonary fibrosis
Lara Bossini-Castillo1*, Carmen P Simeon2, Lorenzo Beretta3, Jasper C Broen4, Madelon C Vonk4,
Raquel Ríos-Fernández5, Gerard Espinosa6, Patricia Carreira7, María T Camps8, Maria J Castillo9,
Miguel A González-Gay10, Emma Beltrán11, María del Carmen Freire12, Javier Narváez13, Carlos Tolosa14,
Torsten Witte15, Alexander Kreuter16, Annemie J Schuerwegh17, Anna-Maria Hoffmann-Vold18,
Roger Hesselstrand19, Claudio Lunardi20, Jacob M van Laar21, Meng May Chee22, Ariane Herrick23,
Bobby PC Koeleman24, Christopher P Denton25, Carmen Fonseca25, Timothy RDJ Radstake26† and Javier Martin1†,
for the Spanish Scleroderma Group
Abstract
Introduction: CD226 genetic variants have been associated with a number of autoimmune diseases and recently
with systemic sclerosis (SSc). The aim of this study was to test the influence of CD226 loci in SSc susceptibility,
clinical phenotypes and autoantibody status in a large multicenter European population.
Methods: A total of seven European populations of Caucasian ancestry were included, comprising 2,131 patients
with SSc and 3,966 healthy controls. Three CD226 single nucleotide polymorphisms (SNPs), rs763361, rs3479968 and
rs727088, were genotyped using Taqman 5’allelic discrimination assays.
Results: Pooled analyses showed no evidence of association of the three SNPs, neither with the global disease nor
with the analyzed subphenotypes. However, haplotype block analysis revealed a significant association for the TCG
haplotype (SNP order: rs763361, rs34794968, rs727088) with lung fibrosis positive patients (PBonf = 3.18E-02 OR 1.27
(1.05 to 1.54)).
Conclusion: Our data suggest that the tested genetic variants do not individually influence SSc susceptibility but a
CD226 three-variant haplotype is related with genetic predisposition to SSc-related pulmonary fibrosis.
Introduction
Systemic sclerosis (SSc) is a connective tissue disorder
in which fibrotic collagen deposition, vascular damage,
autoimmunity and autoantibody production (especially
anticentromere (ACA), and antitopoisomerase, (ATA)
antibodies) are the main hallmarks [1]. SSc patients can
be classified classically in two major subgroups, those
suffering from limited cutaneous SSc (lcSSc) and those
with the diffuse cutaneous form of the disease (dcSSc)
[2].
The genetic component of SSc has been recently rein-
forced and several genes involved in immune regulation
have been proposed as risk factors for the development
of SSc [3]. A number of loci such as IRF5 [4], STAT4
[5,6], BANK1 [7,8], C8orf13-BLK [9,10], CD247 [11,12]
and TNFSF4 [13,14], have been associated with genetic
predisposition to SSc in Caucasian populations. Some of
these loci are shared with other autoimmune diseases,
such as rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE), reinforcing the theory of a com-
mon genetic background in autoimmune diseases [15].
CD226 (cluster of differentiation 226)/PTA1 (platelet
and T-cell activation antigen 1)/DNAM-1 (DNAX acces-
sory molecule 1) is a member of the immunoglobulin
superfamily and it plays an important role in the co-
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groups. Tables S2 to S$4 in Additional file 1 show the gen-
stimulation pathways of natural killer (NK) cells and
activated T cells [16]. Furthermore, CD226 is constitu-
tively expressed on NK cells, CD4+ and CD8+ T cells,
monocytes, platelets and certain B cells playing a pleio-
tropic role in the immune system [16,17], thus subtle
changes in CD226 expression could be involved in SSc
immune imbalance.
CD226 gene polymorphisms have been correlated with
an increasing number of autoimmune pathologies. Thus,
the CD226 rs763361/Gly307Ser non-synonymous poly-
morphism was first correlated to type 1 diabetes sus-
ceptibility [18,19], later to multiple autoimmune diseases
[19,20] and recently, to SSc [21]. Interestingly, the
minor allele rs763361*T encodes a non-synonymous
mutation (Gly307Ser) in the cytoplasmic tail of CD226
protein (exon 7). In addition, the rs763361 glycine to
serine substitution could interfere in the phosphoryla-
tion of CD226 at 322Tyr and 329Ser residues, and the
downstream signaling pathway may be modulated by
these posttranslational modifications [16,22].
In a recent study performed in SLE, a three-variant
haplotype in CD226 gene, comprising CD226 rs763361-
rs34794968-rs727088, was found to be associated with
SLE and the authors proposed that rs727088 may be the
single nucleotide polymorphism (SNP) with a functional
influence on CD226 transcription levels [23].
The aim of this study was to test in a large European
population the previously reported association of CD226
gene rs763361/Gly307Ser with SSc, and to analyze, for
the first time, the role of two additional polymorphisms,
rs34794968 and rs727088, and the effect of CD226
rs763361-rs34794968-rs727088 haplotype in SSc.
Materials and methods
Subjects
A total of 2,131 SSc cases and 3,966 controls from seven
European Caucasian cohorts (Spain, Germany, the Neth-
erlands, Italy, Sweden, the United Kingdom and Nor-
way) were included in this study. Patients were
diagnosed as having SSc using the criteria proposed by
the 1980 ACR and/or LeRoy and Medsger criteria
[24,25]. In addition, patients were classified as having
limited or diffuse SSc as defined by LeRoy et al. [26].
The following clinical data was collected for ascertain-
ment of clinical phenotype of all the patients with SSc:
age, gender, disease duration and presence of SSc-asso-
ciated autoantibodies, ATA and ACA. Pulmonary fibro-
sis was diagnosed by High Resolution Computed
Tomography (HRCT). Considering the previously
reported subphenotype associations, the subtype, auto-
antibody status and pulmonary fibrosis data were avail-
able for all the patients included in this report (Table S1
in Additional file 1 shows these clinical data). The con-
trol population consisted of unrelated healthy
individuals recruited in the same geographical regions as
SSc patients and matched by age, sex and ethnicity with
the SSc patients groups. Local ethical committees from
all the participating centers approved the study. Both
patients and controls were included in the study after
written informed consent.
CD226 genotyping and statistical analysis
Three SNPs, rs763361 and rs3479968 located in exon 7,
and rs727088 in the 3’UTR region were selected as
genetic markers. The SNPs were analyzed by Taqman
SNP genotyping assays in a 7900HT real-time polymer-
ase chain reaction (PCR) System following the manufac-
turer’s suggestions (Applied Biosystems, Foster City, CA,
USA).
All cohorts were in Hardy-Weinberg equilibrium
(HWE) at significance level = 0.01 for all the included
SNPs. PLINK (v1.07) software [27] was used for indivi-
dual population association tests (significance was calcu-
lated by 2 × 2 contingency tables and Fisher’s exact test
or c2 when necessary) and pooled analysis. Bonferroni
and Benjamini and Hochberg false discovery rate
method correction (FDR) were applied for multiple test
correction [28]. In addition, the Breslow-Day test (BD
test) was performed as implemented in PLINK to assess
the homogeneity of the association among populations.
Haplotype pooled analysis was performed by Haploview
(Cambridge, MA, USA) and Statsdirect (Altrincham,
Cheshire, UK) software. Power was calculated using the
software Power Calculator for Genetic Studies 2006 and
assuming an additive model [29].
Results
CD226 rs763361/Gly307Ser, rs34794968 and rs727088
analysis
Table 1 shows the genotype and allelic frequencies and
pooled analyses of the three CD226 SNPs included in
this report in the global disease and the considered sub-
otype and allele distribution of each of the tested
variants in the seven analyzed European cohorts. The
BD test revealed no statistically significant differences
between the seven cohorts included, hence we per-
formed a pooled analysis using the Mantel-Haenszel test
under fixed effects for each of the tested polymorph-
isms. As opposed to Dieudé et al. [21], the pooled ana-
lysis of rs763361 showed no evidence of association
with the whole set of SSc patients. Then, we interro-
gated the major SSc subphenotypes as defined by LeRoy
et al. [26], and in addition by autoantibody status and
by lung fibrosis as described in Dieudé et al.[21]. Allele
frequencies in each subgroup were compared to control
frequencies and no evidence of association was found at
any of the considered subgroups. In addition, we
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observed no significant association in the pooled ana-
lyses of the CD226 rs34794968 and rs727088 genetic
variants with neither the global disease nor with the
considered phenotypic subgroups.
CD226 haplotype block analysis
Considering the CD226 haplotype block association
described in SLE [23], we analyzed the possible effect of
this haplotype block in SSc patients. In this analysis,
considering only haplotypes with frequency > 5% in the
pooled analysis, we reported no significant association
with SSc susceptibility. However, stratification revealed
that the TCG haplotype (SNP order: rs763361-
rs34794968- rs727088) was over-represented in the lung
fibrosis positive subgroup of patients. This haplotype,
composed of the minor alleles of rs763361 and rs727088
Table 1 Genotype and allele distribution of CD226 rs763361 (chr:18, 65,682,622 bp), rs34794968 (chr:18; 65,682,006
bp), rs727088 (chr:18, 65,681,419 bp) genetic variants and pooled analysis.
Genotype, N (%) Allele test
SNP Subgroup (N) 1/1 1/2 2/2 MAF (%) PMH PFDR_BH OR [CI 95%] PBD
rs763361 Controls (n = 3811) 906 (23.77) 1841 (48.31) 1064 (27.92) 47.93
SSc (n = 2023) 480 (23.73) 990 (48.94) 553 (27.34) 48.2 0.56 0.73 1.02 [0.95-1.10] 0.56
lcSSc (n = 1397) 332 (23.77) 681 (48.75) 384 (27.49) 48.14 0.64 0.95 1.02 [0.94-1.11] 0.8
dcSSc (n = 626) 148 (23.64) 309 (49.36) 169 (27.00) 48.32 0.6 0.94 1.03 [0.92-1.17] 0.14
ACA+ (n = 797) 176 (22.08) 396 (49.69) 225 (28.23) 46.93 0.68 0.68 0.98 [0.88-1.09] 0.85
ATA+ (n = 503) 133 (26.44) 239 (47.51) 131 (26.04) 50.2 0.22 0.28 1.09 [0.95-1.24] 0.63
Fib+ (n = 729) 176 (24.14) 359 (49.25) 194 (26.61) 48.77 0.48 0.58 1.04 [0.93-1.17] 0.5
rs34794968 Controls (n = 3858) 669 (17.34) 1842 (47.74) 1347 (34.91) 41.21
SSc (n = 2060) 348 (16.89) 978 (47.48) 734 (35.63) 40.63 0.73 0.73 0.99 [0.91-1.07] 0.37
lcSSc (n = 1422) 234 (16.46) 685 (48.17) 503 (35.37) 40.54 0.74 0.95 0.99 [0.90-1.08] 0.71
dcSSc (n = 638) 114 (17.87) 293 (45.92) 231 (36.21) 40.83 0.94 0.94 1.00 [0.88-1.12] 0.05
ACA+ (n = 816) 129 (15.81) 390 (47.79) 297 (36.40) 39.71 0.35 0.68 0.95 [0.85-1.06] 0.6
ATA+ (n = 518) 100 (19.31) 249 (48.07) 169 (32.63) 43.34 0.28 0.28 1.08 [0.94-1.23] 0.38
Fib+ (n = 755) 122 (16.16) 362 (47.95) 271 (35.89) 40.13 0.58 0.58 0.97 [0.87-1.09] 0.44
rs727088 Controls (n = 3815) 917 (24.04) 1869 (48.99) 1029 (26.97) 48.53
SSc (n = 2042) 489 (23.95) 1014 (49.66) 539 (26.40) 48.78 0.59 0.73 1.02 [0.95-1.10] 0.86
lcSSc (n = 1409) 336 (23.85) 702 (49.82) 371 (26.33) 48.76 0.63 0.95 1.02 [0.94-1.11] 0.66
dcSSc (n = 633) 153 (24.17) 312 (49.29) 168 (26.54) 48.82 0.71 0.94 1.02 [0.91-1.15] 0.26
ACA+ (n = 814) 178 (21.87) 414 (50.86) 222 (27.27) 47.3 0.54 0.68 0.97 [0.87-1.08] 0.56
ATA+ (n = 514) 138 (26.85) 250 (48.64) 126 (24.51) 51.17 0.14 0.28 1.10 [0.97-1.26] 0.61
Fib+ (n = 739) 185 (25.03) 363 (49.12) 191 (25.85) 49.59 0.4 0.58 1.05 [0.94-1.17] 0.86
Controls are used as reference for all comparisons. ACA, anti-centromere antibodies; ATA, anti-topoisomerase antibodies; 95% CI, 95% confidence interval; dcSSc,
diffuse cutaneous systemic sclerosis; Fib+, lung fibrosis positive SSc patients; lcSSc, limited cutaneous systemic sclerosis; MAF, minor allele frequency; NS, not
significant; OR, odds ratio; PBD, Breslow-Day homogeneity test p-value; P FDR_BH, corrected P-value using Benjamini and Hochberg false discovery rate; PMH, allelic
Mantel-Haenszel fixed effects model P-value; SSc, systemic sclerosis.
Table 2 Association of CD226 haplotype block in the Fib+ subset of systemic sclerosis patients.
rs763361 rs34794968 rs727088 Subgroup MAF (%) PMH PBonf OR [CI 95%] PBD
Fib+ 0.40
T A G CTRL 0.41 0.59 NS 0.97 [0.86-1.08] 0.45
Fib- 0.41 0.76 NS 0.98 [0.86-1.11] 0.77
Fib+ 0.10
T C G CTRL 0.08 1.59E-02 3.18E-02 1.27 [1.05-1.54] 0.48
Fib- 0.08 0.069 NS 1.24 [0.99-1.56] 0.51
Fib+ 0.50
C C A CTRL 0.51 0.44 NS 0.96 [0.86-1.07] 0.71
Fib- 0.51 0.50 NS 0.95 [0.84-1.09] 0.44
For the haplotype-specific analyses, the odds ratio (OR) with 95% confidence interval (95% CI) was determined for each allele variant in the haplotype tested
against all of the others pooled together using the Mantel-Haenszel test under fixed effects model, considering no single reference haplotype. CTRL, healthy
controls; Fib-, lung fibrosis negative SSc patients; Fib+, lung fibrosis positive SSc patients; MAF, minor allele frequency; PBonf, corrected P-value using Bonferroni
multiple test correction.
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polymorphisms and the major allele of rs34794968, was
not equivalent to that associated with SLE susceptibility,
but showed a modest risk effect in the lung fibrosis
positive group of patients. This association with lung
fibrosis remained significant even after performing Bon-
ferroni multiple test correction, (PBonf = 3.18E-02 OR
1.27 (1.05 to1.54), Table 2). Remarkably, a trend of asso-
ciation for the TCG haplotype was observed in the com-
parison between the lung fibrosis positive subset of
patients and the fibrosis negative group of patients
(Table 2). We consider that the lack of statistical signifi-
cance may be possibly due to a reduced statistical
power, as the lung fibrosis negative subgroup (n =
1,572) is smaller than the control group (n = 3,966).
Discussion
We carried out a well-powered case-control study aim-
ing to test the contribution of three CD226 genetic var-
iants (rs763361, rs34794968 and rs727088) to SSc
susceptibility and clinical phenotypes. We report the
association of a CD226 three-variant haplotype with
SSc-related pulmonary fibrosis. However, we observed a
lack of individual association of these three CD226 poly-
morphisms with SSc or with its serological and clinical
manifestations.
The allele and genotype frequencies observed in our
control group were similar to those described in the
HapMap public database phase 3 (CEPH: Utah residents
with ancestry from northern and western Europe; abbre-
viation: CEU), and considerably comparable with those
in Dieudé et al. report [21]. Although the present study
did not confirm the previously reported association of
rs763361 with SSc, we found that one of the haplotypes
containing the rs763361*T allele showed evidence of
association with the lung fibrosis positive group of
patients [21]. We consider that the lack of association
for rs763361 individually could have arisen due to a
type II error (false negative), because our sample size is
similar to the study by Dieudé et al. and reaches 99%
power to detect the previously reported effect of the
polymorphism. It is worth mentioning that Dieudé et al.
analyzed this polymorphism both in an Italian and Ger-
man replication cohorts, the latest being the most asso-
ciated with the FA+ group. Consequently our FA+
German cohort, in spite of being smaller than the one
in Dieudé et al., showed the highest trend of association
observed in this group (Table S1 in Additional file 1).
Given the high power of our pooled analysis to detect
similar associations to those reported in the previous
SSc study, our data suggest that the previously reported
effect for the association between CD226 rs763361*T
allele and SSc susceptibility may be influenced by ethni-
cal factors. Remarkably, Dieudé et al. studied the impli-
cation of the amino acid change encoded by rs763361*T
in CD226 expression, but no significant differences were
observed [21]. Our data together with SLE reports [23],
suggest that haplotypic allele combinations might be
considered for further functional studies.
Tao et al. described an increased susceptibility of NKT
cells to apoptosis via CD95-CD95L or TCR-CD3 in
NKT cells isolated from active SLE patients, and linked
it with a deficient expression of CD226 [30]. Later,
genetic studies revealed that rs727088 minor allele was
part of a haplotype associated with SLE susceptibility
and was responsible for a decrease in CD226 gene
expression [23]. Despite experimental evidence of the
role of rs727088 in CD226 transcription modulation in
SLE, we detected no association signal of rs727088 or
the SLE-risk haplotype with SSc susceptibility. These
findings suggest that although CD226 is a common risk
factor for SLE and SSc, the genetic variants in this gene
may have potentially divergent roles in both diseases or
the causal variant might be disease specific. Noteworthy,
it is well-established that SSc and SLE share a number
of associated loci, but the associated variants are not
necessarily the same, for example in the human leuko-
cyte antigen (HLA) region [31]. Considering that fibrosis
is a main hallmark of SSc, the specific association of
CD226 with SSc fibrosis-positive patients might reflect
the influence of this locus in diverse pathways. Interest-
ingly, NLRP1 a common autoimmune disease risk factor
has been reported to be associated with the ATA and
lung fibrosis-positive subgroups of SSc patients [32].
Moreover, NLRP1 was reported to contribute to SLE in
families suffering SLE and vitiligo or other autoimmune
or autoinflammatory diseases [33] and it has been
recently found to be associated with SLE in a Brazilian
population [34]. Nevertheless, rs2670660 and an
rs12150220-rs2670660 haplotype were the associated
variants in SLE, but only rs8182352 was associated with
SSc-related pulmonary fibrosis (although both
rs12150220 and rs2670660 were analyzed) [32,34].
Hence, although the population size in the SLE study is
limited, this differential association in SLE of a novel
SSc fibrosis risk factor is analogous to the reported
CD226 results.
It is well-established that SSc patients exhibit reduced
numbers and impaired function of NKT cells [35-37]
and the highest CD226 expression levels in healthy
donors are found in NKT cells [21,23]. Thus, the impact
of the associated CD226 haplotype reported in this
study on the functions of SSc patients’ NK and NKT
cells should be further explored. Furthermore, new ther-
apeutic approaches based on anti-CD226 mAb treat-
ment have already been tested in autoimmunity animal
models [38], and CD226 has been recently implied in
novel T cell activation pathways [39] and NK-driven tis-
sue injury in SLE patients [40]. Hence, the implication
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of CD226 in cell-mediated cytotoxicity should be con-
sidered. In addition, the possibility of lung fibrosis being
a marker of generalized internal organ damage, which
was not analyzed in this study and represented a limita-
tion of our findings, should be interrogated.
To date just a few loci have been reported to be asso-
ciated with SSc-related pulmonary involvement, such as
IRF5 [6], STAT4 [6], TNFAIP3 [41], KCNA5 [42],
NLRP1 [32] and HGF [43]. Hence, we consider that the
confirmation of CD226 as a pulmonary involvement
marker might be valuable in the deciphering of the
mechanisms that underlie the lung fibrosis process in
SSc patients.
Conclusions
Our data suggest that previously autoimmune-associated
CD226 gene polymorphisms play a role in the SSc pul-
monary fibrosis events in European Caucasian popula-
tions, and confirm CD226 as an important shared
autoimmune factor in SSc.
Additional material
Additional file 1: Population specific characteristics and genotype
and allelic distribution of the three analyzed variants in each
population. This file contains: Table S1 showing the population specific
composition of the complete SSc set of patients for the analyzed
features of the disease; Tables S2 to 4 showing the genotype and allele
distributions of CD226 rs763361, rs34794968 and rs727088 genetic
variants in seven European cohorts.
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